JPX · 4592.T
SanBio Company Limited
¥917-¥27 (-2.86%)
SanBio Company Limited’s quoted price sits in the lower half of its reported 52-week range, 68.74% below the high.
Loading market information…
JPX · 4593.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Healios K.K.’s quoted price sits in the lower half of its reported 52-week range, 45.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Healios K.K.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -¥11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Healios K.K.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 13, 2025 |
| -¥27+8.02% vs estimate |
| ¥38M-89.73% vs estimate |
| Q4 2024 | Feb 12, 2025 | ¥3+124.42% vs estimate | ¥18M+620.0% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -¥17-46.17% vs estimate | ¥34M+6,727.31% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥917-¥27 (-2.86%)
SanBio Company Limited’s quoted price sits in the lower half of its reported 52-week range, 68.74% below the high.
¥3,015-¥75 (-2.43%)
Heartseed, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
¥544+¥33 (+6.46%)
JCR Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.98% below the high.
¥7,060-¥290 (-3.95%)
Cuorips Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
¥629-¥138 (-17.99%)
Japan Tissue Engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.15% below the high.
¥29+¥1 (+3.57%)
AnGes, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.82% below the high.
¥139-¥7 (-4.79%)
StemRIM’s quoted price sits in the lower half of its reported 52-week range, 62.23% below the high.
¥188-¥7 (-3.59%)
CellSeed Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.66% below the high.
